News

Advanced Accelerator Applications S.A. (AAA), a Novartis company, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted…
Read More...

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced a strategic partnership with Seattle-based PharmaIN Corporation for the purpose of investigating the use of…
Read More...

CStone Pharmaceuticals announced that it has received approval to initiate clinical development in China of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced…
Read More...

Reata Pharmaceuticals, Inc. announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treatment of…
Read More...

Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene…
Read More...

Contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions has announced the expansion of its pilot plant facility is now operational at its UK site following…
Read More...

Cambrex Corporation announced that it has completed a new 600 m2 facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development.…
Read More...

Enable Injections, Inc., a company developing and manufacturing advanced wearable infusion devices for combination products, announced it has entered into a multi-product development…
Read More...

Abveris, Inc., a leader in contract research antibody discovery, announced that it has entered into a multi-target agreement with TetraGenetics, Inc. a biopharmaceutical company…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin…
Read More...

GlaxoSmithKline announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending two new methods for…
Read More...

The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides…
Read More...

Aldevron announced expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual…
Read More...

Thermo Fisher Scientific and Newomics will combine their expertise and innovative technologies to develop and optimize sensitive, robust and reproducible microflow LC-MS workflows for…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug Application (sNDA) for…
Read More...

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC)…
Read More...

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), announced that it has entered into a Master Development and Commercialization Agreement with…
Read More...

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s…
Read More...

Particle Sciences, a Lubrizol LifeSciences company and pharmaceutical contract development and manufacturing organization (CDMO), has broadened its Drug Enforcement Administration (DEA)…
Read More...

Merz, a global leader in neurotoxin therapy, announced the European approval of Xeomin (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to…
Read More...